logo
Delay in land allotment hits progress of TN's first medical devices testing lab

Delay in land allotment hits progress of TN's first medical devices testing lab

COIMBATORE: The state government is set to establish the first Medical Devices Testing Laboratory in Coimbatore district for Rs 29.67 crore. However, sources said the project is yet to commence due to delay in land identification process by the district administration.
The Medical Devices Rules, under the Drug and Cosmetics (D&C) Act, came into effect in January 2018, bringing medical devices under the broader umbrella of the Act. It required manufacturers, importers and sellers to obtain necessary permissions for their activities.
Testing medical devices at government-owned laboratories is also a part of the rules. However, the drug administration department in Tamil Nadu has not performed any tests on medical devices due to the lack of a specialised laboratory in the state. After long, the project was officially announced in December 2024. Health Minister Ma Subramanian officially announced the project during demands for grants, sources said.
Based on the proposal from the Director of Drugs Control, Tamil Nadu, the central government approved the plan of establishing a well-equipped NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited laboratory for testing medical devices, including in-vitro diagnostics, exclusively in Coimbatore. In a Memorandum of Understanding (MoU) between the central and state government under the Strengthening of State Drug Regulatory System scheme, Rs 29.67 crore was allocated for the project in mid-2024-25, in a fund sharing ratio of 60:40 by the centre and the state, respectively.
Sources said there has been no progress in setting up the laboratory. "Considering the importance of the standard of medical devices, the central government introduced separate rules to them, and this mandates proper testing at laboratories. Even after the rule came into force, it could not be followed as there is no proper lab facility. While the establishment of the laboratory is expected to play a major role in testing medical devices across the state, the ongoing delay in land identification has raised concerns that the allocated funds might be returned as they remain unused," said sources.
"There are well-equipped laboratories for drugs in Chennai and Madurai. As we have medical device manufacturers in Coimbatore region, and it is also an industrial hub, we chose to establish the device testing laboratory here. This lab is to test class A and B category medical devices. We need around one acre, including 20,000 sqft for the laboratory. Once the Coimbatore district administration identifies the land, we can start work through the Public Works Department. We sent a letter to the Coimbatore district collector, and a communication through the health secretary. We hope to get the land allotment soon," said MN Sridhar, Director of Drugs Control.
Coimbatore District Collector Pavankumar G Giriyappanavar said, "We have shortlisted few parcels of lands, and will finalise it at the earliest as we are in the final stage of confirming the land."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cohance Lifesciences announces USD 10 mn investment in US-based arm
Cohance Lifesciences announces USD 10 mn investment in US-based arm

News18

time10 minutes ago

  • News18

Cohance Lifesciences announces USD 10 mn investment in US-based arm

New Delhi, Aug 12 (PTI) Cohance Lifesciences on Tuesday announced a strategic investment of USD 10 million (around Rs 87.6 crore) to expand bioconjugation capabilities at its US-based subsidiary, NJ Bio. The investment advances Cohance's global expansion in niche technology-led modalities, enhancing its ability to support innovators from early development through late-phase clinical supply, the company said in a statement. The common good manufacturing practices (cGMP) compliant bioconjugation suite at NJ Bio's Princeton, New Jersey, facility significantly strengthens the company's capabilities to deliver fully integrated Antibody-Drug Conjugate (ADC) solutions, it added. 'The investment … strengthening our footprint in the rapidly growing ADC space. By integrating payload-linker development and bioconjugation capabilities under one roof, NJ Bio will be well-positioned to support accelerated development timelines and help bring life-saving therapies to patients faster," Vivek Sharma, Executive Chairman, Cohance Lifesciences, said. In a separate statement, Cohance announced a Rs 23 crore investment and significant progress on its new oligonucleotide building block manufacturing facility in Hyderabad. 'Together, these investments form part of Cohance's planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply," the company said. Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global Contract Research, Development, and Manufacturing Organization (CRDMO), formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. PTI MSS MR view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

Apollo Hospitals Q1 Results: Cons PAT surges 42% YoY to Rs 433 crore, revenue rises 15%
Apollo Hospitals Q1 Results: Cons PAT surges 42% YoY to Rs 433 crore, revenue rises 15%

Time of India

timean hour ago

  • Time of India

Apollo Hospitals Q1 Results: Cons PAT surges 42% YoY to Rs 433 crore, revenue rises 15%

Apollo Hospitals Enterprise on Tuesday reported a consolidated net profit of Rs 433 crore in Q1, up 42% compared to Rs 305 crore reported in the year ago period. The profit after tax (PAT) was attributable to the owners of the company. Company's revenue from operations in the quarter grew 15% to Rs 5,842 crore versus Rs 5,086 crore in Q1FY25. Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program The PAT was 11% higher on a sequential basis versus Rs 390 crore in Q4FY25 while the topline increased 4.5% over Rs 5,592 reported by the company in Q4FY25. The earnings were announced after market hours and Apollo Hospitals shares ended with minor downtick at Rs 7,253 on the NSE. Segment revenue The company earned its revenues from healthcare services, Retail health & diagnostics, Digital health & pharmacy distribution and also as other income. -- Healthcare services revenue stood at Rs 2,974 crore in Q1FY26 versus Rs 2,843 crore in Q4FY25 and Rs 2,654 crore in Q1FY25. -- Retail health & diagnostics revenue stood at Rs 435 crore in Q1FY26 versus Rs 394 crore in Q4FY25 and Rs 366 crore in Q1FY25. -- Digital health & pharmacy distribution revenue stood at Rs 2,472 crore in Q1FY26 versus Rs 2,376 crore in Q4FY25 and Rs 2,082 crore in Q1FY25. Also Read: Nykaa Q1 Results: Cons PAT soars 79% YoY to Rs 24 crore, revenue jumps 23% Q1 Expenses The company's expenses were reported at Rs 5,313 crore, up on a YoY and QoQ basis. In the previous quarter, Apollo Hospitals had reported expenses of Rs 5,148 crore while Rs 4,704 crore in the year ago period. The expenses were made on material used by the hospital, purchases of stock-in-trade, employee benefits and as finance cost. Acquisition The company's Board of Directors today approved an investment of Rs 8.5 crore for acquiring 85 lakh equity shares of Apollo Gleneagles PET-CT Private Limited (AGPCL) from its existing shareholder, Parkway Healthcare (Mauritius) PTE Limited, representing capital of AGPCL. Also Read: NSDL Q1 Results: Cons PAT jumps 15% YoY to Rs 90 crore despite 7% drop in revenue

Dr Agarwals Health Care records Q1 net profit at Rs 17.26 cr
Dr Agarwals Health Care records Q1 net profit at Rs 17.26 cr

News18

timean hour ago

  • News18

Dr Agarwals Health Care records Q1 net profit at Rs 17.26 cr

Chennai, Aug 12 (PTI) Dr Agarwal's Health Care Ltd has reported a net profit of Rs 17.26 crore for the April-June 2025 quarter on the back of a robust performance, the eye care provider said on Tuesday. The city-based firm earned a net profit of Rs 14.11 crore during the corresponding quarter of the last fiscal. For the year ending March 31, 2025, the consolidated net profit was at Rs 54.65 crore, the company said in a press release here. The total income for the quarter under review surged to Rs 117.72 crore, from Rs 100.42 crore registered in the year ago period. For the financial year ending March 31,2025 the total income was at Rs 402.24 crore. Commenting on the financial performance, Dr Agarwal's Health Care Ltd, CEO Dr Adil Agarwal said, 'the first quarter of the new fiscal year has started with a robust performance." 'We are pleased to report the highest-ever revenue on a quarterly basis, with profit margins sustaining at high levels. Total income for the quarter stood at Rs 501 crore, a growth of 22.3 per cent over the same period of last year driven by healthy growth across our network," he said. Agarwal said, 'Operationally, our network grew to 249 eye care facilities as of June 30, 2025, with 13 additions during the quarter. We also marked our strategic entry into the Delhi market, opening our first centre in the capital to strengthen our presence in North India." 'We remain committed to expanding our footprint, investing in advanced technologies, and delivering superior clinical outcomes to our patients," he said. During the April-June 2025 quarter, Dr Agarwal's Health added 1 tertiary, 7 secondary and 5 primary care facilities. It performed 78,882 surgeries during the quarter under review, up by 16 per cent year-on-year basis. The sales of services during the quarter under review contributed 78.6 per cent, while sale of products accounted for 21.4 per cent to the revenue from operations. PTI VIJ VIJ ROH (This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store